Cargando…

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy. METHODS: DPD and hENT1 immunohistochemistry and scoring was c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Campbell, F., Costello, E., Halloran, C. M., Mackey, J. R., Scarfe, A. G, Valle, J. W., McDonald, A. C., Carter, R., Tebbutt, N. C., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B., Deakin, M., Charnley, R. M., Anthoney, Alan, Lerch, M. M., Mayerle, J., Oláh, A., Büchler, M. W., Greenhalf, W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931115/ https://www.ncbi.nlm.nih.gov/pubmed/29515256 http://dx.doi.org/10.1038/s41416-018-0004-2

Ejemplares similares

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy
por: Elander, N. O., et al.
Publicado: (2018)

Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
por: Royer, B., et al.
Publicado: (2023)

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
por: Donadio, Mauro Daniel Spina, et al.
Publicado: (2022)

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
por: Paulsen, Niels Herluf, et al.
Publicado: (2022)

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
por: Dive, C, et al.
Publicado: (2010)

Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
por: Akhter, Khaleda, et al.
Publicado: (2019)

The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer
por: Kleeff, Jörg, et al.
Publicado: (2016)

Linking COVID-19 and Acute Pancreatitis Through the Pathogenic Effects of the SARS-CoV-2 S Protein Subunit 1 on Pancreatic Stellate Cells and Macrophages
por: Neoptolemos, J P, et al.
Publicado: (2022)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
por: Raffenne, Jerome, et al.
Publicado: (2019)

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker
por: Scully, Paul R., et al.
Publicado: (2020)

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
por: Martens, Forike K., et al.
Publicado: (2020)

Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
por: Smith, R A, et al.
Publicado: (2011)

Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency
por: van Staveren, Maurice C., et al.
Publicado: (2011)

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
por: McLeod, H. L., et al.
Publicado: (1998)

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer
por: Horiguchi, J, et al.
Publicado: (2002)

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
por: Neoptolemos, J P, et al.
Publicado: (2009)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis
por: Laures, Nicolas, et al.
Publicado: (2022)

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
por: White, Cassandra, et al.
Publicado: (2021)

Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma
por: Mann, Kulbir, et al.
Publicado: (2019)

Delayed Presentation of DPD Deficiency in Colorectal Cancer
por: Law, Lindsey, et al.
Publicado: (2014)

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer
por: Stocken, D D, et al.
Publicado: (2005)

iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance
por: Tonack, S, et al.
Publicado: (2013)

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
por: Spratlin, Jennifer L., et al.
Publicado: (2010)

Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses
por: Sultana, A, et al.
Publicado: (2008)

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
por: Ridge, S. A., et al.
Publicado: (1998)

Synthesis and Characterization of Functionalized Amino Dihydropyrimidines Toward the Analysis of their Antibacterial Structure–Activity Relationships and Mechanism of Action
por: Boyer, Zachary W., et al.
Publicado: (2022)

P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION
por: Montefusco, V., et al.
Publicado: (2023)

Simulation of tetraetherlipids on solid surfaces – an extension of the DPD-model
por: Engels, Christoph, et al.
Publicado: (2008)

A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity
por: Offer, Steven M., et al.
Publicado: (2013)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
por: Maring, J G, et al.
Publicado: (2002)

Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy
por: Sultana, A, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_qmckg3bnfkdj0v7j5mggpa2rpu